A phase II study of pembrolizumab combination with temozolomide as 1L treatment for Chinese metastatic acral melanoma patients
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs Pembrolizumab (Primary) ; Temozolomide (Primary)
- Indications Acral lentiginous melanoma; Malignant melanoma
- Focus Therapeutic Use
- 20 Jan 2025 New trial record